Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 16, 2006, Pages 4349-4353

  Jonathan Fray, M ^a   Bish, Gerwyn ^a   Fish, Paul V ^a   Stobie, Alan ^a   Wakenhut, Florian ^a   Whitlock, Gavin A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Depression; Incontinence; Neurotransmitters; Noradrenaline; Reuptake inhibition; Serotonin

Indexed keywords

CARRIER PROTEIN; CYTOCHROME P450; DULOXETINE; FLUOXETINE; FUNCTIONAL GROUP; HETEROCYCLIC COMPOUND; NORADRENALIN UPTAKE INHIBITOR; PHENYL GROUP; PIPERAZINE DERIVATIVE; REBOXETINE; RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

AMINE TRANSPORT; ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; ENANTIOMER; ENZYME INHIBITION; HUMAN; HUMAN CELL; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION;

AMINES; BIOLOGICAL TRANSPORT; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; PIPERAZINES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745781487     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.049     Document Type: Article

References (15)

1. Fray, M. J.; Bish, G.; Brown, A. D.; Fish, P. V.; Stobie, A.; Wakenhut, F.; Whitlock, G. A.; Bioorg. Med. Chem. Lett., preceding paper.
2. Reith, M. E. A. Neurotransmitter Transporters: Structure, Function and Regulation, 2nd ed., Humana Press: Totowa, NJ, 2002.
3. Iversen L. Mol. Psychiatry 5 (2000) 357
4. Schatzberg A.F. J. Clin. Psychiatry 61 Suppl. 11 (2000) 9
5. Barker E.L., and Blakely R.D. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, Philadelphia 21
6. Bump R.C., Norton P.A., Zinner N.R., and Yalcin I. Obstet. Gynecol. 102 (2003) 76
7. Katritzky A.R., Yannakopoulou K., Lue P., Rasala D., and Urogdi L. J. Chem. Soc. Perkin Trans. 1 (1989) 225
8. Katritzky A.R., Strah S., and Belyakov S.A. Tetrahedron 54 (1998) 7167
9. Dondoni A., Fantin G., Fogagnolo M., Medici A., and Pedrini P. Synthesis (1987) 998 now available commercially
10. N-Boc piperazine and N-Boc homopiperazine were purchased from Sigma-Aldrich. The organometallic reagents used were either obtained commercially or generated from the commercial benzyl/naphthylmethyl/picolyl chloride or bromide immediately prior to use.
11. HPLC conditions: for (+)-1, (-)-1: Chiralcel OJ column, eluting with hexane/ethanol/diethylamine 80:20:0.2, detection at 254 nm; for (+)-2 and (-)-2 Chiralcel OD column, eluting with hexane/isopropanol/diethylamine 70:30:0.3, detection at 254 nm.
12. Absolute configuration was determined by a single crystal X-ray diffraction study of the edisylate salt, grown by slow evaporation from methanol.
13. 50 = 4 nM would have 95% confidence intervals of 1.4-6.6 nM.
14. Boot J.R., Brace G., Delatour C.L., Dezutter N., Fairhurst J., Findlay J., Gallagher P.T., Hoes I., Mahadevan S., Mitchell S.N., Rathwell R.E., Richards S.J., Simmonds R.G., Wallace L., and Whatton M.A. Bioorg. Med. Chem. Lett. 14 (2004) 5395
15. Bymaster F.P., Beedle E.E., Findlay J., Gallagher P.T., Krushinski J.H., Mitchell S.N., Robertson D.W., Thompson D.C., Wallace L., and Wong D.T. Bioorg. Med. Chem. Lett. 13 (2003) 4477